| Autor: |
Johan, Spetz, Britta, Langen, Nils-Petter, Rudqvist, Toshima Z, Parris, Emman, Shubbar, Johanna, Dalmo, Bo, Wängberg, Ola, Nilsson, Khalil, Helou, Eva, Forssell-Aronsson |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
EJNMMI Research |
| ISSN: |
2191-219X |
| Popis: |
Background 177Lu-octreotate is used for therapy of somatostatin receptor expressing neuroendocrine tumors with promising results, although complete tumor remission is rarely seen. Previous studies on nude mice bearing the human small intestine neuroendocrine tumor, GOT1, have shown that a priming injection of 177Lu-octreotate 24 h before the main injection of 177Lu-octreotate resulted in higher 177Lu concentration in tumor, resulting in increased absorbed dose, volume reduction, and time to regrowth. To our knowledge, the cellular effects of a priming treatment schedule have not yet been studied. The aim of this study was to identify transcriptional changes contributing to the enhanced therapeutic response of GOT1 tumors in nude mice to 177Lu-octreotate therapy with priming, compared with non-curative monotherapy. Results RNA microarray analysis was performed on tumor samples from GOT1-bearing BALB/c nude mice treated with a 5 MBq priming injection of 177Lu-octreotate followed by a second injection of 10 MBq of 177Lu-octreotate after 24 h and killed after 1, 3, 7, and 41 days after the last injection. Administered activity amounts were chosen to be non-curative, in order to facilitate the study of tumor regression and regrowth. Differentially regulated transcripts (RNA samples from treated vs. untreated animals) were identified (change ≥ 1.5-fold; adjusted p value |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink